Printer Friendly

Orphazyme appoints new CEO.

M2 PHARMA-July 16, 2019-Orphazyme appoints new CEO

(C)2019 M2 COMMUNICATIONS

Orphazyme A/S (CPH:ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, announced on Monday the appointment of Kim Stratton as the new CEO, effective 1 October 2019. Stratton succeeds Anders Hinsby.

According to Orphazyme, as it enters a new chapter in its development, from being an entrepreneurial R&D company to a company with significant growth aspirations, an emerging late-stage pipeline and moving into the pre-commercial phase, Hinsby had initiated discussions with the board of directors to resign from his position as CEO. Hinsby had co-founded Orphazyme ten years ago and has led its successful evolution. Reportedly, Hinsby will remain with the company through the transition period.

Stratton, who has over 25 years of global commercial experience from biopharmaceuticals, most recently was with Shire Pharmaceuticals, where she served as head International Commercial for Shire's Specialty and Rare Diseases portfolio.

Before Shire, she spent nearly 15 years at Novartis in a number of senior management roles, including global product development, commercial, marketing, general manager and various global corporate functions, including government and external affairs.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 16, 2019
Words:203
Previous Article:Gilead Sciences signs 10-year global research and development collaboration with Galapagos.
Next Article:Genomma Lab Internacional receives Sanitary License from Mexican health commission.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters